Press Releases

Press Releases

Date Title
25 November 2020 BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies
25 November 2020 BioNTech and Fosun Pharma Announce the Start of a Phase 2 Clinical Trial of Lead mRNA COVID-19 Vaccine BNT162b2 in China
20 November 2020 Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
18 November 2020 Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
16 November 2020 BioNTech and Fosun Pharma receive approval to commence COVID-19 Vaccine Candidate BNT162b2 trial in China
11 November 2020 Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19
10 November 2020 BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress
9 November 2020 Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
3 November 2020 BioNTech to Report Third Quarter 2020 Financial Results and Operational Update on November 10, 2020
14 October 2020 Pfizer and BioNTech Announce New England Journal of Medicine Publication of Phase 1 Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
14 October 2020 BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting
9 October 2020 Pfizer Canada and BioNTech Initiate Rolling Submission to Health Canada for SARS-CoV-2 Vaccine Candidate BNT162b2
6 October 2020 BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
30 September 2020 BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data from mRNA-based Vaccine Candidate BNT162b1 Against SARS-CoV-2
17 September 2020 BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021
15 September 2020 BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162
12 September 2020 Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
9 September 2020 Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19
9 September 2020 Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
8 September 2020 Biopharma Leaders Unite to Stand with Science
7 September 2020 BioNTech and Pfizer Receive Regulatory Approval From Paul-Ehrlich-Institut to Commence German Part of Global Phase 2/3 Trial for COVID-19 Vaccine Candidate BNT162b2
27 August 2020 BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 mRNA-based Vaccine Candidate Against SARS-CoV-2 to Hong Kong SAR and Macao SAR
20 August 2020 Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
12 August 2020 Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARS-CoV-2 in Nature
11 August 2020 BioNTech Announces Second Quarter 2020 Financial Results and Corporate Progress
6 August 2020 BioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020
5 August 2020 Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate
5 August 2020 BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China
31 July 2020 Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate
31 July 2020 BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma
30 July 2020 BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature
27 July 2020 Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
27 July 2020 BioNTech Announces Closing of $512 Million Underwritten Offering of American Depositary Shares
22 July 2020 BioNTech Announces Pricing of Upsized Underwritten Offering and Terms of Rights Offering
22 July 2020 Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
21 July 2020 BioNTech Announces Proposed Public Offerings
20 July 2020 Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
20 July 2020 Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
13 July 2020 Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
1 July 2020 BioNTech to Hold Webcast to Present Early Positive Data from Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
1 July 2020 Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
29 June 2020 BioNTech to Raise USD 250 Million in Private Placement
11 June 2020 Investment Plan for Europe: European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing
12 May 2020 BioNTech Announces First Quarter 2020 Financial Results and Corporate Progress
6 May 2020 BioNTech Completes Acquisition of Neon Therapeutics
5 May 2020 Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
5 May 2020 BioNTech to Report First Quarter 2020 Financial Results and Operational Update on May 12, 2020
29 April 2020 BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany
22 April 2020 BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates
9 April 2020 Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
31 March 2020 BioNTech Announces Full Year 2019 Financial Results and Corporate Update
23 March 2020 BioNTech to report full year financial results for 2019 and provide corporate update on the fourth quarter on March 31, 2020
17 March 2020 Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine
16 March 2020 BioNTech and Fosun Pharma form COVID-19 vaccine strategic alliance in China
16 March 2020 BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat
3 February 2020 BioNTech Announces Commencement of Public Offering of American Depositary Shares
16 January 2020 BioNTech to acquire Neon to strengthen global leadership position in T cell therapies
13 January 2020 BioNTech Appoints Ryan Richardson as Chief Strategy Officer to Support its Continued Global Expansion
2 January 2020 BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BioNTech disavows any obligation to update the information contained in such press releases after the date of their issuance.